Evaluate the Efficacy of Cystone-SF Liquid in diabetic subjects suffering from Chronic UTI
- Conditions
- Health Condition 1: N390- Urinary tract infection, site notspecified
- Registration Number
- CTRI/2020/03/024271
- Lead Sponsor
- The Himalaya Drug Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Adult male and female subjects aged >=18 to <= 65 years presenting atleast two of the following UTI symptoms like urgency, dysuria, frequency of micturition (nos), suprapubic pain, haematuria, burning micturition, fever, flank pain, chills, nausea and emesis.
Known diabetic subjects with controlled blood sugar levels (RBS between 130 to 150 mg/dL).
Three or more episodes of recurrent UTI in the past 12 months.
UTI as diagnosed by urine culture more than 105 CFU/mL
Urine routine microscopy suggestive of increase or normal number of pus cells (white blood cells) per cubic millimetre
Subjects willing to sign informed consent and follow the study procedure.
Subjects who has not participated in any similar kind of clinical study in the last one month.
History of neurogenic bladder, pelvic irradiation or chemical cystitis, Presence of urethral, pelvic, or rectal carcinoma, Benign or malignant bladder tumors, Tuberculous cystitis, urinary schistosomiasis.
Subjects with cardiac, neurological, renal or hepatic dysfunction.
Pregnant & breast-feeding women.
Significant medical problems such as uncontrolled hypertension / congestive heart failure or any other medication condition
History of ongoing, chronic or recurrent infectious disease / lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.
History of Alcohol or smoking abuse.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method